GlassScriptPhysician profile
Reinaldo Gonzalez Laportilla
NPI 1104270032
$4,524.87
in general payments reported to CMS, 2019-2025
28 companies · $854 in 2025
The $854 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $1,030 · 2023: $992 · 2024: $814 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574 · Education: $86.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.23 |
| Education | $86.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,130.39 | 2021-2025 | Erleada, Akeega |
| Pfizer INC. | $546.89 | 2022-2025 | |
| Astellas Pharma US INC | $429.60 | 2022-2023 | Myrbetriq |
| Abbvie INC. | $385.03 | 2021-2025 | |
| Tolmar Pharmaceuticals, INC. | $345.66 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $272.10 | 2023-2025 | Gemtesa |
| Verity Pharmaceuticals INC. | $234.06 | 2022-2025 | Tlando, Trelstar |
| Tolmar, INC. | $169.19 | 2023-2025 | Eligard, Jatenzo |
| Boston Scientific Corporation | $144.87 | 2021-2024 | |
| Endo Pharmaceuticals INC. | $141.97 | 2021 | |
| Merck Sharp & Dohme LLC | $98.53 | 2021-2023 | Keytruda, Lynparza |
| Clarus Therapeutics INC. | $83.32 | 2021 | |
| Medtronic, INC. | $72.84 | 2023 | Interstim |
| Urovant Sciences INC | $65.81 | 2021 | |
| Convatec INC. | $49.27 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.32 | 2022 | |
| Antares Pharma, INC. | $39.72 | 2024 | Xyosted |
| Endo USA, INC. | $35.79 | 2025 | Xiaflex |
| Acerus Pharmaceuticals Corporation | $35.45 | 2022 | |
| Janssen Scientific Affairs, LLC | $34.55 | 2022 | |
| Myovant Sciences INC. | $29.72 | 2021 | |
| 180 Medical, INC. | $27.41 | 2021 | |
| Axonics, INC. | $19.69 | 2022 | |
| Blue Earth Diagnostics | $19.19 | 2022 | |
| Davol INC. | $18.79 | 2023 | Arista Ah Flexitip |
| Mission Pharmacal Company | $18.71 | 2022 | |
| Immunitybio, INC. | $18.45 | 2025 | |
| Myriad Genetic Laboratories, INC. | $16.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reinaldo Gonzalez Laportilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.